NCT00712855 - A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2012

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL

mapatumumab

3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle

DRUG

sorafenib

400 mg orally, twice a day continuously in each cycle

Trial Locations (6)

University of Pennsylvania- Abramson Cancer Center, Philadelphia

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

University of Florida, Gainesville

Mayo Clinic, Rochester

University of Colorado Cancer Center, Aurora

Cedars-Sinai Health System, Los Angeles